Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
A. INCLUSION CRITERIA~1. Patients must be ≥1 and ≤ 21 years of age when enrolled onto this study.~2. Diagnosis~   * Patients must have a diagnosis of relapsed or refractory AML or ALL and,~  * Patient must have an M1 marrow based upon a recovered marrow with less than 5% blasts by conventional morphology and,~  * Patient must have minimal residual disease (MRD) detected by either multidimensional or conventional flow cytometry greater than 0.1% and less than 5% following any re-induction attempt and~  * Patients must be CNS 1.~3. Patient must have an ANC \>500/μL off cytokine support for at least 24 hours and platelets \>50,000 K/μL without platelet transfusion in the past seven days~4. Performance Level Karnofsky \> 50% for patients \> 16 years of age and Lansky \> 50% for patients ≤16 years of age.~5. Patient must have adequate venous access.~6. Prior Therapy~   1. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.~  2. At least 21 days must have elapsed from prior chemotherapy, at least 7 days must have elapsed since receiving biological therapy.~  3. It must be at least 45 days from any higher dose cytarabine therapy (\>1 gm/ m2/day).~  4. Patients on steroid taper must be on less than 0.5mg/kg/day with plans to continue taper and discontinue the steroids.~7. Renal and Hepatic Function Patient must have adequate renal and hepatic functions as indicated by the following laboratory values:~   1. Patients must have a normal calculated creatinine clearance as calculated below:~      * Pediatric Population (age \<18): Calculated creatinine clearance ≥ 90 ml/min/1.73m2 as calculated by the Schwartz formula for estimated glomerular filtration rate (GFR) where GFR (ml/min/1.73 m2) = k\*Height (cm)/serum creatinine (mg/dl). k is a proportionality constant which varies with age and is a function of urinary creatinine excretion per unit of body size; 0.45 up to 12 months of age; 0.55 children and adolescent girls; and 0.70 adolescent boys.~     * Adult Population (age ≥18): Serum creatinine ≤1.0 mg/dL; if serum creatinine \>1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is black.~  2. Conjugated (direct) serum bilirubin ≤ 1.5 x ULN for age.~  3. Alanine transaminase (ALT) ≤ 2.5 × ULN for age.~  4. Alkaline phosphatase ≤ 2.5 × ULN for age.~  5. Serum amylase ≤ 1.5 ULN for age.~  6. Serum Lipase is ≤ ULN for age.~8. Patient must have a shortening fraction \> 28% by echocardiogram or an ejection fraction \> 50% by MUGA~9. Reproductive Function~   1. Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.~  2. Female patients with infants must agree not to breastfeed their infants while on this study.~  3. Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.~10. Patient must agree to submission of blood and bone marrow for MPF assessment of MRD to TACL centralized lab.~B. EXCLUSION CRITERIA~Patients will be excluded if they meet any of the following criteria:~1. Patients with previous HSCT within previous 180 days.~2. Patients who have had prior treatment with clofarabine.~3. Patients with CNS2 or CNS 3 disease or bulky chloromatous disease.~4. Patients with Down Syndrome.~5. Patients with a previous history of veno-occlusive disease (VOD) or findings consistent with a diagnosis of VOD, defined as: conjugated serum bilirubin \>1.4 mg/dL AND unexplained weight gain greater than 10% of baseline weight or ascites AND hepatomegaly or right upper quadrant pain without another explanation, OR reversal of portal vein flow on ultrasound, OR pathological confirmation of VOD on liver biopsy.~6. Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).~7. Use of investigational agents within 30 days of planned treatment on this protocol.~8. Patient is receiving or plans to receive concomitant chemotherapy, radiation therapy, immunotherapy or other anti-cancer therapy other than is specified in the protocol.~9. Pregnant or lactating patients.~10. Any significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.~11. Have had a diagnosis of another malignancy, unless the patient has been disease-free for at least 3 years following the completion of curative intent therapy with the following exceptions:~    1. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.~   2. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.~12. Patient has active acute (greater than grade II) or active chronic extensive GVHD. Patients who are on a tapering dose of immunosuppressants will be permitted (tapering calcineurin inhibitor and/or less than 0.5 mg/kg/day of steroids).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): A maximum of two courses of the following regimen will be administered.~* Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~* Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~* Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~* Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).